問卷

TPIDB > Study Site

Study Site



Chi Mei Medical Center

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 710Tainan CityTainan Yongkang

篩選

List

421Cases

2025-07-01 - 2035-12-31

Phase III

Not yet recruiting
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)
  • Condition/Disease

    Breast Neoplasms

  • Test Drug

    注射劑 錠劑 注射劑 注射劑

Participate Sites
7Sites

Recruiting7Sites

2018-08-01 - 2025-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2016-08-01 - 2018-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2011-03-01 - 2012-06-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2020-08-01 - 2025-04-07

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2019-06-01 - 2024-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-10-01 - 2022-08-24

Phase I/II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2022-11-01 - 2037-11-01

Others

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2022-04-01 - 2027-12-31

Phase I/II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2010-11-01 - 2019-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites